Fig. 6

Subgroups divided by FCER1G expression predict potential immunotherapy responses of gliomas. a The fraction of TILCs in FCER1G high and low subgroups. Within each group, the scattered dots represent TILCs expression values. The thick line represents the median value. The bottom and top of the boxes are the 25th and 75th percentiles, interquartile range. The whiskers encompass 1.5 times the interquartile range. The statistical difference of three gene clusters was compared through the Kruskal–Wallis test. b The correlation between the expression of FCER1G and PDCD1 (b) and CTLA4 c in CGGA cohort. d T-cell inflammatory signature (TIS) scores across FCER1G subgroups. A plot presents a single glioma sample. Red line indicates the median value. e Rates of the different anti-PD1 and anti-CTLA4 responses of patients from the CGGA cohort predicted by the ImmunCellAI (Left, Chi-square test, P < 0.01) and Tumor Immune Dysfunction and Exclusion (TIDE) web program (Right, Chi-square test, P < 0.01) in the high or low FCER1G subgroups. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001